Clinical trials: Salmonella Infection
Typhoid
Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh
This is a double blinded, randomized-controlled, non-inferiority trial of a typhoid conjugate vaccine, Typhocon (Vi- polysaccharide conjugated to diphtheria toxoid, Vi-DT), manufactured by a local company, Incepta Vaccine…
- Trial name
- NCT05475379
- Testing
- Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)
- Where
- Bangladesh
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Typhoid Fever
Commercial Typhoid Tests Validation
The study aims to perform a head to head comparison of 11 typhoid tests currently in the market and simultaneously develop a sample set that can be used in future evaluations of emerging technologies.
- Trial name
- NCT04673487
- Testing
- 1. SD Bioline Salmonella Typhi IgG/IgM Fast test, 2. Typhidot Rapid IgG/IgM combo test, 3. TUBEX TF test, 4.Typhoid IgG/IgM Combo Rapid Test CE, 5. Enterocheck WB test, 6. Test-itTM Typhoid IgM test
- Where
- Kenya
- Volunteers
- 2,000 people
- Sponsor
- Kenya Medical Research Institute
Typhoid Fever
Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)
This trial is aimed to evaluate the safety and immunogenicity profiles of three formulations of Vi-CRM197 conjugate vaccine against S.
- Trial name
- NCT01193907
- Testing
- NVGH Vi-CRM197 12.5 mcg, NVGH Vi-CRM197 5.0 mcg, NVGH Vi-CRM197 1.25 mcg
- Where
- Belgium
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza, Hepatitis A
Effects of Aging on Primary and Secondary Vaccine Responses
The purpose of this study is to use an existing, unique clinical cohort: the longitudinal cohort of younger (21-40 years) and elderly (>65 years) subjects whose yearly influenza vaccine responses have been studied extensively…
- Conditions
- Influenza, Hepatitis A, Typhoid, Healthy Adults
- Trial name
- SLVP033 (NCT03312699)
- Testing
- Fluzone® quadrivalent, Fluzone High Dose, Fluad
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Stanford University
Typhoid Fever
Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age
Typhoid fever remains an important cause of morbidity and mortality in the developing world. It is estimated that more than 16 million cases and about 600,000 deaths occur annually, most of which occur in Southeast Asia and…
- Trial name
- NCT00386789
- Where
- 4 sites in United States, Vietnam
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Typhoid Fever
Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers
This is a multicenter (at travel clinics), phase 4 observational prospective cohort study in healthy adult male and female travelers for whom typhoid vaccination with Vivotif is recommended, as per standard practice.
- Trial name
- NCT02391909
- Testing
- Vivotif
- Where
- United States
- Volunteers
- 855 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Salmonella Infections
A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults
The current clinical study will evaluate the GVGH Quadrivalent Pan-Salmonella vaccine for the first time in healthy adults in Africa.
- Trial name
- NCT07663032
- Testing
- Pan-Salmonella-with-Alum (Low dose) vaccine, Pan-Salmonella-with-Alum (Full dose) vaccine, Pan-Salmonella-without-Alum (Low dose) vaccine
- Where
- South Africa
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Typhoid Fever
Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults
The purpose of this study is to evaluate the immunogenicity and the kinetics of the anti-Vi antibody response following secondary vaccination with the Novartis Vaccines Institute for Global Health (NVGH) Vi-CRM197 vaccine in…
- Trial name
- NCT01438996
- Testing
- NVGH Vi-CRM197
- Where
- Belgium
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Novartis
Typhoid Fever
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
This trial is aimed to evaluate the safety and immunogenicity profiles of a new Vi-CRM197 conjugate vaccine against S. Typhi in healthy human adults in comparison with the currently licensed Vi polysaccharide vaccine.
- Trial name
- NCT01123941
- Testing
- Typherix, NVGH Vi-CRM197
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novartis
Hepatitis A
Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity
To evaluate the immunogenicity, reactogenicity and safety of Hepatyrix when compared to the concomitant administration of Typherix and Havrix, and when compared to the administration of monovalent vaccines, Havrix or Typhim Vi.
- Trial name
- NCT00197249
- Testing
- Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix
- Volunteers
- 1,034 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Salmonella Infections
A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever
The purpose of this study is to assess the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid…
- Trial name
- NCT05480800
- Testing
- Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose, Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose, Typhoid conjugate vaccine (TCV) low dose
- Where
- 2 sites in Belgium, Malawi
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Typhoid Fever, Intestinal Perforation
TyVECO: Surveillance Protocol
In Kisantu Health Zone, approximate population 200,000, fever surveillance will be implemented in 8 health centers and 1 tertiary hospital.
- Trial name
- TyVECO (NCT05562102)
- Testing
- Typbar-TCV, Bharat Biotech
- Where
- 9 sites in Democratic Republic of the Congo
- Volunteers
- 48,000 people
- Sponsor
- International Vaccine Institute
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Salmonella Infections, Infection of Bloodstream
Reservoir of Invasive Salmonellosis in Children, DRC
Bloodstream infections caused by non-typhoid Salmonella (NTS) are a major killing disease in Sub-Saharan Africa. Despite the high case fatality rate, the main reservoir -human, zoonotic or environmental- for invasive NTS rests…
- Trial name
- NCT03073707
- Testing
- Sample collection
- Where
- Democratic Republic of the Congo
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Typhoid
Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine
This is a Multicenter, observer-blinded, randomized, Active controlled, Phase 3 study in healthy 6 months to 45 years aged Nepalese at the time of the first vaccine dose. The study objectives are: I.
- Trial name
- NCT03933098
- Testing
- Test Vaccine Vi-DT Typhoid conjugate, Control Vaccine Typbar TCV®
- Where
- 4 sites in Nepal
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Salmonella Septicemia, Salmonella Infections
IDIS Project Work Package 2: Establishing a Biobank at ITM and Collaborating Centres
The IDIS study aims to develop a new rapid diagnostic test for invasive salmonellosis using samples (blood, urine) collected from patients with fever and healthy controls at the Institute of Tropical Medicine (ITM) and…
- Conditions
- Salmonella Septicemia, Salmonella Infections, Fever, Blood Stream Infections
- Trial name
- IDIS (NCT02689193)
- Testing
- Blood sampling
- Where
- 3 sites in Belgium, Cambodia and 1 more
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Typhoid Fever
Global Genomic and Proteomic Profiling of African Children With Typhoid Fever
To develop a rapid, sensitive, and inexpensive diagnostic method, as well as more efficacious vaccine, for countries where typhoid fever remains a major public health burden.
- Trial name
- NCT02947295
- Where
- Nigeria
- Volunteers
- 969 people
- Sponsor
- University of Nebraska
Typhoid Fever
Effectiveness of a Typhoid Conjugate Vaccine in DRC
This is a prospective cohort evaluation of vaccine effectiveness of a single dose of Typbar-TCV® against symptomatic blood culture-confirmed typhoid fever when administered through a mass vaccination campaign to children 9 months…
- Trial name
- TyVECO (NCT05119426)
- Testing
- Vi-TT
- Where
- 25 sites in Democratic Republic of the Congo
- Volunteers
- 48,000 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Weight Gain, Anemia, Iron Deficiency
Egg Intervention During Pregnancy in Indonesia
The study consists of two arms: 1) intervention group using eggs as supplementary food given from 2nd trimester of pregnancy to birth, and 2) observational group of pregnant mothers.
- Conditions
- Weight Gain, Anemia, Iron Deficiency, Birth Weight, Birth Length
- Trial name
- PRECODE (NCT04694235)
- Testing
- Egg intervention
- Where
- Indonesia
- Volunteers
- 702 people, healthy volunteers welcome
- Sponsor
- SEAMEO Regional Centre for Food and Nutrition
Typhoid Fever
The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)
Typhoid and paratyphoid (enteric) fever affects more than 11 million children and adults globally each year including 7 million in South Asia.
- Trial name
- ACT-South Asia (NCT04349826)
- Testing
- Azithromycin, Cefixime
- Where
- Nepal
- Volunteers
- 2,150 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam